Deracoxib (BioDeep_00000272946)

   


代谢物信息卡片


Deracoxib

化学式: C17H14F3N3O3S (397.0707930000001)
中文名称: 地拉考昔
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: COC1=C(C=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)F)F
InChI: InChI=1S/C17H14F3N3O3S/c1-26-16-7-2-10(8-13(16)18)15-9-14(17(19)20)22-23(15)11-3-5-12(6-4-11)27(21,24)25/h2-9,17H,1H3,(H2,21,24,25)

描述信息

D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents
D002491 - Central Nervous System Agents > D000700 - Analgesics
C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor
D000893 - Anti-Inflammatory Agents
D004791 - Enzyme Inhibitors

同义名列表

1 个代谢物同义名

Deracoxib



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Chao Wan, Jian-Yu Pang, Wei Jiang, Xiao-Wei Zhang, Xiang-Guo Hu. Copper-Catalyzed Reductive Ring-Cleavage of Isoxazoles: Synthesis of Fluoroalkylated Enaminones and Application for the Preparation of Celecoxib, Deracoxib, and Mavacoxib. The Journal of organic chemistry. 2021 03; 86(6):4557-4566. doi: 10.1021/acs.joc.0c02980. [PMID: 33586981]
  • Daniel J Warner, Hongming Chen, Louis-David Cantin, J Gerry Kenna, Simone Stahl, Clare L Walker, Tobias Noeske. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals. 2012 Dec; 40(12):2332-41. doi: 10.1124/dmd.112.047068. [PMID: 22961681]
  • Kathleen B Mullins, John M Thomason, Kari V Lunsford, Lesya M Pinchuk, Vernon C Langston, Robert W Wills, Ronald M McLaughlin, Andrew J Mackin. Effects of carprofen, meloxicam and deracoxib on platelet function in dogs. Veterinary anaesthesia and analgesia. 2012 Mar; 39(2):206-17. doi: 10.1111/j.1467-2995.2011.00684.x. [PMID: 22248445]
  • J L Davis, J F Marshall, M G Papich, A T Blikslager, N B Campbell. The pharmacokinetics and in vitro cyclooxygenase selectivity of deracoxib in horses. Journal of veterinary pharmacology and therapeutics. 2011 Feb; 34(1):12-6. doi: 10.1111/j.1365-2885.2010.01185.x. [PMID: 21219338]
  • S Cox, J Yarbrough. Determination of firocoxib in equine plasma using high performance liquid chromatography. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2011 Jan; 879(2):205-8. doi: 10.1016/j.jchromb.2010.11.026. [PMID: 21185237]
  • J N King, C Rudaz, L Borer, M Jung, W Seewald, P Lees. In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. Research in veterinary science. 2010 Jun; 88(3):497-506. doi: 10.1016/j.rvsc.2009.11.002. [PMID: 20004922]
  • Shauna L Blois, Dana G Allen, R Darren Wood, Peter D Conlon. Effects of aspirin, carprofen, deracoxib, and meloxicam on platelet function and systemic prostaglandin concentrations in healthy dogs. American journal of veterinary research. 2010 Mar; 71(3):349-58. doi: 10.2460/ajvr.71.3.349. [PMID: 20187838]
  • E S Roberts, K A Van Lare, B R Marable, W F Salminen. Safety and tolerability of 3-week and 6-month dosing of Deramaxx (deracoxib) chewable tablets in dogs. Journal of veterinary pharmacology and therapeutics. 2009 Aug; 32(4):329-37. doi: 10.1111/j.1365-2885.2008.01043.x. [PMID: 19614837]
  • Benjamin M Brainard, Craig P Meredith, Mary Beth Callan, Steven C Budsberg, Francis S Shofer, Bernd Driessen, Cynthia M Otto. Changes in platelet function, hemostasis, and prostaglandin expression after treatment with nonsteroidal anti-inflammatory drugs with various cyclooxygenase selectivities in dogs. American journal of veterinary research. 2007 Mar; 68(3):251-7. doi: 10.2460/ajvr.68.3.251. [PMID: 17331013]
  • Adam D Gassel, Karen M Tobias, Sherry K Cox. Disposition of deracoxib in cats after oral administration. Journal of the American Animal Hospital Association. 2006 May; 42(3):212-7. doi: 10.5326/0420212. [PMID: 16611933]
  • David L Panciera, Kent R Refsal, Kathleen A Sennello, Daniel L Ward. Effects of deracoxib and aspirin on serum concentrations of thyroxine, 3,5,3'-triiodothyronine, free thyroxine, and thyroid-stimulating hormone in healthy dogs. American journal of veterinary research. 2006 Apr; 67(4):599-603. doi: 10.2460/ajvr.67.4.599. [PMID: 16579752]
  • Stephen R Royals, James P Farese, Rowan J Milner, Linda Lee-Ambrose, James van Gilder. Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs. American journal of veterinary research. 2005 Nov; 66(11):1961-7. doi: 10.2460/ajvr.2005.66.1961. [PMID: 16334957]
  • Sherry K Cox, Jacob Roark, Adam Gassel, Karen Tobias. Determination of deracoxib in feline plasma samples using high performance liquid chromatography. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2005 May; 819(1):181-4. doi: 10.1016/j.jchromb.2005.01.025. [PMID: 15797537]
  • T D Penning, J J Talley, S R Bertenshaw, J S Carter, P W Collins, S Docter, M J Graneto, L F Lee, J W Malecha, J M Miyashiro, R S Rogers, D J Rogier, S S Yu, AndersonGD, E G Burton, J N Cogburn, S A Gregory, C M Koboldt, W E Perkins, K Seibert, A W Veenhuizen, Y Y Zhang, P C Isakson. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). Journal of medicinal chemistry. 1997 Apr; 40(9):1347-65. doi: 10.1021/jm960803q. [PMID: 9135032]